Charles River Laboratories International Inc at Morgan Stanley Healthcare Conference Transcript
Good morning, everybody. It is my pleasure to introduce our next guest for the day.
To my left is Jim Foster, CEO of Charles River. I think you all know Charles River is a contract research organization and really a market leader in the preclinical segment.
And Jim, when we think about your business, you have a very broad scope of portfolio: Toxicology, animal model, discovery. And you've -- in a great position and have been to really benefit from the increased biopharma spend. So with that in mind, you can take a few minutes just to help frame the conversation for us and just kind of like walk us through what are you seeing in the overall market?
Yes. I would say that biotech has been a principal driver of our growth for probably 5 or 6 years now. And I don't really know when the crossover was, but we were always the supplier to pharma. And I'd say 8 or 9 years ago, biotech sort of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
